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Introduction: Traditional clonogenic survival and high throughput 
colorimetric assays are inadequate as drug screens to identify novel 
radiation sensitizers. We developed a method that we call the high 
content clonogenic survival assay (HCSA) that will allow screening 
of drug libraries to identify candidate radiation sensitizers.
Methods: Drug screen using HCSA was done in 96 well plates. 
After drug treatment, irradiation, and incubation, colonies were 
stained with crystal violet and imaged on the INCell 6000 (GE 
Health). Colonies achieving 50 or more cells were enumerated using 
the INCell Developer image analysis software. A proof-of-principle 
screen was done on the KRAS mutant lung cancer cell line H460 and 
a Custom Clinical Collection (146 compounds).
Results: Multiple drugs of the same class were found to be radia-
tion sensitizers and levels of potency seemed to reflect the clini-
cal relevance of these drugs. For instance, several PARP inhibitors 
were identified as good radiation sensitizers in the HCSA screen. 
However, there were also a few PARP inhibitors not found to be sen-
sitizing that have either not made it into clinical development, or in 
the case of BSI-201, was proven to not even be a PARP inhibitor. 
We discovered that inhibitors of pathways downstream of activated 
mutant KRAS (PI3K, AKT, mTOR, and MEK1/2) sensitized H460 
cells to radiation. Furthermore, the potent MEK1/2 inhibitor trame-
nitib selectively enhanced radiation effects in KRAS mutant but not 
wild-type lung cancer cells.
Conclusions: Drug screening for novel radiation sensitizers is fea-
sible using the HCSA approach. This is an enabling technology that 
will help accelerate the discovery of novel radiosensitizers for clini-
cal testing.
Key Words: Drug screen, Radiation, Clonogenic survival assay, 
KRAS, Lung cancer
(J Thorac Oncol. 2014;9: 965–973)
Radiation plays an important role in the treatment of can-cer of all types. For a number of diseases, adding che-
motherapy to radiation as a sensitizer has improved survival 
outcomes by improving locoregional disease control com-
pared with radiation alone, but the improvement has only been 
modest.1 Further advancements in the field require accurate 
strategies to identify novel agents that could enhance radia-
tion responses. One potential approach is to screen for drugs 
based on synthetic lethality, a well-described phenomenon in 
genetics where lethality to the cell is induced only if two or 
more genes are inactivated, but not so when individual genes 
are inactivated.2 This mechanism is seen in the susceptibil-
ity of BRCA1 or BRCA2 mutant breast or ovarian cancers to 
PARP inhibition,3–6 and for sensitivity to cell cycle inhibitors 
(chk1 and chk2, wee1, polo-like kinase, and aurora-kinase 
inhibitors) of TP53 mutant cancers treated with DNA damag-
ing agents such as radiation and/or chemotherapy.7–9 Synthetic 
lethality screens have been employed to identify interacting 
genes using shRNA libraries10,11 or with drug libraries for 
combination drug therapies,12 but have not been done with 
radiation treatment. Although radiation sensitization with 
drugs is not technically defined as synthetic lethality, in that 
it is not a radiation enhancement in the face of genetic sus-
ceptibility, the output could be similar in that drugs can block 
pathways or molecules that mimic a genetic “hit,” and in that 
setting, radiation stress could render the cells more suscep-
tible to cytotoxic injury. This could be the basis of sensitizer 
screens, identifying compounds that have little to no effects on 
the cancer cells themselves, but have significant synergy with 
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radiation. However, current approaches for testing sensitiz-
ers are difficult to perform simultaneous screens of numerous 
compounds. Current standard procedure approach for testing 
radiation sensitizers is the clonogenic survival assay (CSA). 
It is a robust and reproducible technique but is low through-
put and impractical for drug screening. Various methods have 
been used to screen for radiation sensitizers, such as cell pro-
liferation colorimetric assay,13 colorimetric sulforhodamine B 
assay,14 or γH2AX foci formation assay,15 but such approaches 
do not appropriately identify compounds that inhibit low cell 
density clonogenic survival and therefore may not appropriate 
for radiation screening of compounds.16 We sought to develop 
a method that would facilitate drug screen with radiation, cap-
italizing on the power of the traditional clonogenic survival 
assay in a higher throughput, less cumbersome format.
MATERIALS AND METHODS
Cell Culture
The non–small-cell lung cancer (NSCLC) cell lines 
H460, A549, H661, H1299, H2030, and EKVX were acquired 
courtesy of Dr. John D. Minna (UT Southwestern, Dallas, TX) 
and were maintained in RPMI-1640 medium supplemented 
with 10% fetal bovine serum and 2 mM L-glutamine (Life 
Technologies, Grand Island, NY). U251, DU145, Miapaca2, 
and PC3 were obtained from the NCI DCTD cell repository 
and grown in RPMI-1640 supplemented with 5% fetal bovine 
serum. Cells were grown at 37°C under 5% CO
2
 atmosphere 
in a humidified incubator.
Traditional CSA (tCSA)
Single cell suspension were created by trypsinizing less 
than 90% confluent monolayer of cells with 0.1% trypsin/eth-
ylenediaminetetraacetic acid and seeded at various cell num-
bers depending on the dose in triplicates in 6 well plates at 
3 ml media per well. After overnight incubation for less than 
24 hours, drugs were added to the plates at IC
30
 concentra-
tions, and 6 hours later, the plates were irradiated at specified 
doses in 2 Gy increments, media exchanged at 72 hours, and 
incubated for an additional 10–14 days. The colonies were 
stained with 0.5% crystal violet in 50/50 methanol/water for 
10 minutes, washed, dried, and counted manually. All in vitro 
irradiations were done using a Co-60 gamma irradiator from 
a decommissioned clinical gamma irradiator using a 10 cm × 
10 cm field size at isocenter.
High Content Clonogenic Survival Assay
Single cell suspension were seeded at varying densities 
(1–400 cells per well depending on the amount of radiation 
used to treat the plates; for 2 Gy-50 cells, for 4 Gy-100 cells, 
for 6 Gy-200 cells) into standard 96 well tissue culture plates 
(BD Biosciences, San Jose, CA), in a total volume of 100 μl per 
well. After seeding the plates were placed in a humidified tissue 
culture incubator at 37°C and 5% CO
2
 overnight but less than 
24 hours. Drugs at 11-fold the final concentration or diluent 
were added at 10 μl per well (see details below) and incubated 
for another 6 hours before sham or irradiation. Plates were kept 
in the tissue culture incubator for an additional 4 days without 
disturbance, and colonies were stained with crystal violet as 
done for tCSA, washed, dried, and colonies enumerated by the 
IN Cell Analyzer 6000 (GE Healthcare, Pittsburgh, PA).
Automated High Throughput 
Microscopy Imaging Analysis 
After crystal violet staining, the dried plates were placed 
into an automated plate loader (Peak Analysis and Automation, 
Inc., Colorado Springs, CO) and loaded automatically into the 
IN Cell Analyzer 6000 equipped with a 5.5 Mp large field-of-
view sCMOS camera. Images from four overlapping fields per 
well (5% overlap between fields) were collected from each 
well using a 4×/0.20NA Nikon lens with 642 nM excitation 
and 706 nM emission. Four independent images were stitched 
together into a single composite image for further analysis by 
the GE IN Cell Developer software (version1.9). Image analysis 
began by identifying the individual cell colonies. Once the colo-
nies were identified, the number of individual cell nuclei within 
each colony were identified and counted using masks generated 
from intensity and object filers. The analysis algorithm enumer-
ated the total number of colonies per plate and linked the total 
number of cells with each identified colony. Colonies with 50 
or more cells were reported. There were situations where colo-
nies overlapped. In these cases, the colonies and the cells con-
tained within were counted as a single colony (Supplementary 
Figure 2, SDC 1, http://links.lww.com/JTO/A592).
Drug Screening with HCSA Method
One-hundred forty-six drugs representing targeted agents 
to various pathways (either first generation tool compounds to 
drugs in clinical testing or FDA approved) were arrayed in two 96 
well plates (see Supplementary Figure 3B, SDC 1, http://links.
lww.com/JTO/A592). The compounds were screened using the 
quantitative high throughput screening method as described by 
Inglese et al.17 where each assay plate became a point on the 
concentration response curve thus all of the compounds could 
be screened on the plate at once. Ten microliters of drugs were 
dissolved and diluted to 0.1% DMSO in growth media ranging 
from 10 pM to 11 μM by full log dilutions and were added to 
four assay plates. Two of the four replicate plates were irradi-
ated at 2 Gy, whereas the other two plates were brought to the 
irradiator but not irradiated (sham treatment). This process was 
repeated for each drug concentration. Drug-induced radiation 
sensitization was determined by comparing the colony count 
of each well with a drug added in the sham-treated plates to the 
corresponding well on a similarly treated plate that was irradi-
ated. A drug was considered a radiosensitizer if there was more 
than a 25% reduction in the number of colonies containing 50 
or more cells at a particular dose with radiation treatment than 
the corresponding well without radiation treatment.
Signaling Analysis
Protein lysates were produced by the addition of radio-
immunoprecipitation assay buffer with protease inhibitors to 
monolayers of cells irradiated or not irradiated, with or without 
the addition of drug, scraped, resuspended by pipetting, cen-
trifuged, and resuspended in SDS-PAGE loading dye, boiled 
for 5 minutes, and 50 mg protein were loaded per lane of a 
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10–15% SDS-PAGE gel. Immunoblotting was performed using 
antibodies against total ERK, phospho-ERK, and pAKT. Beta-
actin was used to check for protein loading (all antibodies were 
acquired from Cell Signaling Technology, Danvers, MA).
Gamma-H2AX Staining
Immunofluorescence for gamma-H2AX was done at 
various time increments up to 24 hours after gamma irradia-
tion. Cells were fixed with 4% paraformaldehyde, washed, 
permeabilized, and antibody against gamma-H2AX (Cell 
Signaling Technology, Danvers, MA; 1:100) were added to the 
cells and incubated at 4°C overnight. Cells were then washed 
and incubated with fluorescein isothiocyanate-conjugated 
secondary antibody for 1 hour at room temperature, washed, 
mounted, and visualized with a fluorescence microscope.
Cell Cycle Analysis
Cells were pretreated with 30 nM trametinib (Selleckchem.
com, Houston, TX) for 6 hours and gamma irradiated. The cells 
were then placed back in the incubator, and at various times 
after irradiation, the cells were washed in phosphate-buffered 
saline, trypsinized, fixed, and stained with propidium iodide + 
RNase A. Flow cytometry was conducted using a Gallios Flow 
Cytometer (Beckman Coulter, Indianapolis, IN).
Tumor Growth Delay
Animals were maintained in an Association for the 
Assessment and Accreditation of Laboratory Animal Care 
approved facility in accordance with current regulations of 
the US Department of Agriculture and Department of Health 
and Human Services. Experimental methods were approved 
by and in accordance with institutional guidelines established 
by the Institutional Animal Care and Use Committee. Tumor 
xenografts were produced in the leg of male NCr nu/nu mice 
by intramuscular inoculation of 1 × 106 H460 cells in 10 μL. 
Irradiation and trametinib treatment were started when tumors 
reached 8-mm diameter. Trametinib (2 mg/kg) as a daily oral 
gavage in the morning was given either alone or with irradia-
tion 6 hours after the drug dose. Drug treatment lasted a total 
of 14 days. Drug treatment was done concurrently with daily 
irradiation with 2 Gy in the first 5 days of treatment. Tumor 
growth was determined using thrice weekly caliper measure-
ments. Mice were euthanized by CO
2
 inhalation when tumors 
reached 15 mm in diameter.
Data Analysis
Plating efficiency (PE) for both tCSA and high content 
clonogenic survival assay (HCSA) methods was estimated by 
dividing the number of colonies by the number of cells seeded 
in an otherwise untreated plate. This number was used for nor-
malization in calculating the survival fraction, by the equa-
tion: SF = number of colonies / (number of cells seeded; PE). 
Survival curves were generated with the use of Sigma Plot.
The growth-delay effect of trametinib with radiation 
(enhancement factor [EF]) was quantified as the ratio of dif-
ferences between times required to reach 12 mm diameter:
EF =
       Time to 12 mm (Drug + radiation)
 Time to 12 mm − (Vehicle + radiation)
    Time to 12 mm (Drug) 
Time to 12−  mm (Vehicle)
The times to reach 12 mm were estimated from the param-
eters of linear regressions of the four growth curves, with fits 
limited to the segments of the curves that were linear (growth 
was linear for times longer than 4 days for vehicle, longer than 
6 days for vehicle + radiation, longer than 12 days for Drug, 
and longer than 16 days for drug + radiation). 95% confidence 
intervals for EF were estimated from nonparametric boot-
strapping of the above ratio of differences in times calculated 
from linear regressions of the growth curves.
RESULTS
Development of a High Content Drug 
Screen for Radiation Sensitizers
In the tCSA, the two most cumbersome and time con-
suming steps are initial plating of cells and final colony quanti-
fication (Fig. 1A). The initial plating step in the tCSA requires 
handling of large amounts of growth media and dishes or plates. 
The final step requires long incubation periods to allow single 
cell clones to reach colony sizes of ≥50 cells. Although auto-
mated colony counters have greatly streamlined the process 
from the manual one in the past, the throughput is still not 
feasible for screening multiple drugs at different concentra-
tions. Adapting tCSA for high content drug screening requires 
streamlining these steps by seeding cells in a 96 well plate 
format and automating colony inclusion and enumeration. 
To determine whether it is feasible to miniaturize the tCSA, 
which we will henceforth call the HCSA, the lung cancer cell 
line H460 was seeded at different cell numbers and placed in 
culture to assess clonogenicity. We found that single cells were 
able to grow discretely as single colonies, reaching colony sizes 
of ≥50 cells by day 5, and reflect the PE (or number of colo-
nies formed divided by number of cells seeded) expected of 
this cell line using traditional approaches (~50–70%; Fig. 1B, 
Supplementary Figure 1A, SDC 1, http://links.lww.com/JTO/
A592). A similar experiment was done with another KRAS 
mutant lung cancer line A549 and despite differences in growth 
characteristic (more spread out and mesenchymal like), simi-
lar results of single colony generation were obtained (Fig. 1C). 
We found the colony counts and PE of replicate wells between 
plates and at different times were quite reproducible, generating 
around the same number of colonies depending on the numbers 
of cells seeded on day zero (Supplementary Figure 1B, SDC 
1, http://links.lww.com/JTO/A592). There was an absolute 20% 
reduction in PE with 2 Gy radiation, and the levels remain fairly 
constant between 10 and 200 cells, after which PE dropped off 
significantly when colonies became too crowded to allow for 
accurate automated enumeration (Supplementary Figure 1C, 
SDC 1, http://links.lww.com/JTO/A592). Flow activated cell 
sorting could be used for cell seeding for adaptation for robotic 
cell culture workstations; however, PE was reduced by ~40% 
using flow activated cell sorting when compared with manual 
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multichannel pipetting, which is probably gentler on the cells 
and has less impact on clonogenic survival (Supplementary 
Figure 1D, SDC 1, http://links.lww.com/JTO/A592). We next 
determined whether HCSA could reproduce the same clono-
genic survival results as obtained from tCSA. This was done for 
the H460 and several other cancer lines of various origins (PC3, 
DU145: prostate; Miapaca2: pancreas; U251: GBM). We found 
HCSA recapitulated the same results in terms of the survival 
curve and produced similar surviving fraction at 2 Gy (SF2) for 
most of the cancer cell types tested (Fig. 1D,E).
To determine whether HCSA could be used to identify 
radiosensitizing compounds, we tested vorinostat (SAHA), a 
FIGURE 1.  The high content clonogenic survival assay (HCSA) recapitulates results from traditional clonogenic survival assay 
and allows the identification of radiation sensitizers. A, comparison in techniques between traditional and HCSA methods. The 
workflow on the left panel depicts the typical workflow of the traditional assay, whereas the right panel depicts workflow for the 
HCSA. The length of arrows corresponds to the relative length of time it takes to execute each of the steps. (B) Left panel: crys-
tal violet stain and low magnification images of the triplicate wells from a 96 well plate with cells seeded at various densities per 
well. Right panel: INCell6000 images of the corresponding wells. (C) A comparison of the colonies formed by two lung cancer 
cell lines with different morphologies, one the H460 that forms tighter aggregates whereas the A549 expresses mesenchymal 
characteristics and grows colonies in patterns that are more spread out. The image software was able to enumerate colonies of 
both types, as depicted by the image analysis. (D) Comparison in survival curves between the traditional and HCSA methods. 
HCSA recapitulates a similar survival curve as produced by the traditional method. (E) The survival fraction at 2 Gy (SF2) com-
paring various cell types: glioblastoma (U251), prostate cancer (DU145, PC3), and pancreatic cancer (Miapaca2).
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HDAC inhibitor well known to radiosensitize,18,19 in both tCSA 
and the HCSA. As expected, 1 μM vorinostat for 72 hours 
caused a significant radiation sensitizing effect using tCSA, 
with a dose enhancement ratio of 2.78 (Fig. 2A). Using HCSA, 
we also found that 200 and 400 nM vorinostat dose dependently 
enhanced radiation effect, with enhancement ratios of 1.49 and 
2.27, respectively (Fig. 2B,C). We performed a similar compari-
son using another known radiation sensitizer, DNA-PK/p110α 
inhibitor PI-103.20 Because of the basal potency of this drug, 
the radiation enhancement effect was not as profound as seen 
in the tCSA, but the effect was still dose dependent (Fig. 2D-F).
HCSA Identifies Classes of Sensitizers 
Directed at Kras Mutant Lung Cancer
Supplementary Figure 3A, SDC 1, http://links.lww.
com/JTO/A592, shows the schema for HCSA for screening 
of drug libraries. We used the clinically relevant radiation 
dose of 2 Gy and seeded 50 cells per well. After cell seed-
ing and overnight incubation, serially diluted drugs from 10 
pM to 1 μM were added to the cells in duplicates and incu-
bated for 6 hours before irradiation. We screened two custom 
clinical collections 1 and 2 (146 compounds) that contained 
many small molecules in clinical testing with a few that were 
FDA approved (Supplementary Figure 3B, SDC 1, http://
links.lww.com/JTO/A592). Each drug plate was tested in 
duplicates and the colonies in replicate wells were averaged 
(Fig. 3A). We identified several compounds that were cyto-
toxic to the cells alone (inhibitors to Chk, Aurora Kinase, 
PLK, PKC, proteasome) and some very potent compounds 
such as HSP90 inhibitors that killed cells at low nM concen-
trations. As expected, many of the HDAC inhibitors had some 
sensitizing effect to radiation (a leftward shift in the concen-
tration that inhibits 50% curve by approximately 10-fold). 
However, many of the drugs exhibited significant radiation 
sensitizing effect with some or no activity by themselves, 
such as inhibitors to PARP, SRC, DNA-PK, mTOR, and 
MEK1/2. A summary of radiation enhancers found from the 
HCSA screen is listed in Figure 3B. We found not all drugs 
of the same class were radiation sensitizers. For instance, of 
the 6 PARP inhibitors, only 3 were found to be radiosensitiz-
ing with little cytotoxicity by themselves, with the order of 
potency observed being AG014699 > AZD2281 >> ABT888. 
No activity was seen for BSI-201, DR2313, and NU1025 
(Fig. 3C). Similarly, the HDAC inhibitors Trichostatin, 
PXD101, PCI-24781 exhibited cytotoxicity with little radia-
tion enhancement effects, whereas drugs like NVP LAQ824, 
JNJ-264815, LBH589, MGCD0103, MS-275, and vorinostat 
showed varying degrees of cytotoxic potencies and were 
enhanced by radiation by approximately 10-fold. In addi-
tion, we also found that suppression of clonogenic survival 
by many inhibitors of the downstream effectors of activated 
mutant KRAS (PI3K, AKT, mTOR, MEK) was enhanced 
by radiation (Fig. 3B). This demonstrates that for this Kras 
mutant NSCLC cell line H460, in addition to known sensi-
tizers such as HDAC and PARP inhibitors, drugs that block 
FIGURE 2.  Validation of the HCSA method to identify radiation sensitizers using vorinostat and PI-103. A, one micromolar vori-
nostat was used for the tCSA method, but at such doses no clonogens were produced in the HCSA, and therefore lower doses 
(200 and 400 nM) were used (B-C). High content clonogenic survival assay had very similar enhancement effects compared with 
tCSA, with a dose-dependent radiation enhancement effect. DER, dose enhancement ratio as a radiation dose of control over 
drug at survival fraction 0.5 (SF0.5). (D) 500 nM PI-103 was added to seeded cells for 6 hours before irradiation at indicated 
doses. Media was changed at 72 hours of total drug exposure. (E) PI-103 at 25 or 50 nM (F) was added to seeded cells for 6 
hours before irradiation at corresponding doses. Cells were not perturbed until crystal violet staining on day 5.
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downstream of Kras signaling also sensitizes these cells to 
the effects of radiation.
The MEK Inhibitor GSK1120212 (Trametinib) 
Selectively Sensitizes Kras Mutant Lung 
Cancer Cells to Radiation Treatment
To determine whether inhibition to downstream signal-
ing of Kras specifically sensitized KRAS mutant lung cancer 
cells, we focused on the MEK1/2 inhibitors, given the impor-
tance of the recent clinical development of this drug in KRAS 
mutant lung cancer.21 We found many of the compounds in the 
class of MEK1/2 inhibitors were radiation sensitizers with vari-
able potency between drugs. The first generation compounds 
CI-1040 and PD98059, which are low potency drugs not in 
clinical development, had relatively no independent effect. 
However, several of the later generation MEK inhibitors such 
as PD0325901, AZD6244, and RDEA119 exhibited some sin-
gle agent activity but whose effect were greatly accentuated in 
combination with radiation (Fig. 3C). Given the more advanced 
clinical development, potency, and bioavailability profile of the 
MEK1/2 inhibitor GSK1120212 (trametinib),22 we tested this 
compound in greater detail in additional cell lines. We found 
trametinib used at IC
30
 concentration was a potent radiation 
sensitizer in KRAS mutant lung cancer cell lines but not in 
the 3 wild-type cell lines tested (Fig. 4A). In both the H460 
and A549 cells, radiation significantly enhanced pERK expres-
sion, which was not apparent in the Kras wild-type cell lines 
H661 and H1299 (Fig. 4B, Supplementary Figure 4, SDC 1, 
http://links.lww.com/JTO/A592). This pERK expression was 
FIGURE 3.  High content clonogenic survival assay enables the identification of classes of radiation sensitizers through drug 
screening. A, representative screening results of plate one of the Custom Clinical Collection (CC1) and plate two of the collec-
tion (CC2) on the H460 cells, with the identity of the drugs on the right side of each row of cells. The columns represent one 
drug concentration or sham control, and each row depicts one particular drug. #N/A are blanks with 0.1% DMSO or RPMI. A 
green block represents single agent activity without apparent radiation enhancement effect, a pink block represents drugs that 
are weakly enhancing (<1 log10 shifted) and red block represents drugs that are strongly enhancing (≥1 log10 shifted). (B) List of 
drugs that are identified in the screen to have significant enhancement effects. Drugs within the same class are listed together. 
The inset figure illustrates with asterisks a few of the proteins along the signaling cascade of activated KRAS that radiosensitize 
when blocked. (C) Examples of three classes of radiosensitizing drugs identified in the screen, namely the HDAC inhibitors, PARP 
inhibitors, and MEK inhibitors.
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abolished with trametinib treatment and caused a paradoxical 
increase in pAKT activity, likely because of feedback inhibi-
tion on EGFR/PI3K/AKT activation by MEK/ERK23 (Fig. 
4B). We tested whether AKT inhibition would synergize with 
radiation in addition to trametinib and found that there were no 
additional effects with this drug combination (Supplementary 
Figure 5, SDC 1, http://links.lww.com/JTO/A592). This sug-
gests that feedback upregulation of PI3K/AKT from MEK inhi-
bition does not attenuate the radiation enhancement response. 
We explored the mechanism by which trametinib sensitized 
H460 cells to radiation and found that trametinib and radiation 
did not enhance DNA damage (as assessed by γH2AX foci; 
Supplementary Figure 6A,B, SDC 1, http://links.lww.com/JTO/
A592) or induce apoptosis (by PARP cleavage, Supplementary 
Figure 6C, SDC 1, http://links.lww.com/JTO/A592), but instead 
induced prolonged cell cycle arrest at G2/M (Supplementary 
Figure 7, SDC 1, http://links.lww.com/JTO/A592) and signifi-
cantly reduced the S-fraction over 96 hours (Fig. 4C), leading to 
increased senescence over radiation alone, but not significantly 
greater than MEK inhibition alone (data not shown). Using 
the H460 cells in a xenograft model, trametinib in combina-
tion with 2 Gy × 5 fractions of radiation significantly prolonged 
tumor growth delay (enhancement factor = 1.86 at 12 mm [95% 
CI = 1.23–3.05]) compared with either agent alone (Fig. 4D).
DISCUSSION
In the present study, we show that HCSA is a novel plat-
form to help discover drugs that can be combined with radia-
tion for cancer therapy. The technique is sensitive enough to 
simultaneously detect small radiation enhancement effects 
FIGURE 4.  The MEK inhibitor trametinib is a selective radiation sensitizer in KRAS mutant lung cancer cells. A, traditional 
clonogenic survival assay was used to determine the relative potency of trametinib (MEKi) in various lung cancer cell lines, 
with or without KRAS mutations. This effect seems to be selective in cells lines with KRAS mutations, also the potency differ 
between the KRAS mutant lines. No effect was apparent in the wild-type (WT) cells. (B) Radiation-induced pERK activation that 
was seen in the H460 but not in the WT H661 cell line. This activation was fully blocked by treating cells with trametinib. (C) 
Cell cycle analysis in two KRAS mutant and two KRAS WT cells. Significant S phase prolongation and diminution of G1/S cells 
was apparent in the KRAS mutant cells treated with trametinib and radiation, but not seen with either agent alone or in the WT 
cell lines. (D) Xenograft model of H460 cells to determine the amount of growth delay with combined treatments versus single 
agent alone. Drug treatment lasted 14 days, the first 5 were combined with radiation at 2 Gy per day. Drugs were given by oral 
gavage at 2 mg/kg 4 hours before radiation administration.
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by multiple drugs. We identified several drugs belonging to 
distinct classes of inhibitors that blocked specific pathways. 
This revealed apparent cellular processes that were syntheti-
cally lethal with radiation. One of the well-known sensitizer 
class of drugs are the PARP inhibitors. Of the six that were in 
our library, three came out to be radiation sensitizers, with a 
potency order of AG014699 > AZD2281 >> ABT888. All three 
of these drugs are in various phases of clinical testing combined 
with chemotherapy, and ABT888 is currently being tested with 
chemoradiation in locally advanced NSCLC in a phase I/II 
trial (Southwest Oncology Group 1206). The three other drugs, 
BSI-201, DR2313, and NU1025, had no activity in the HCSA 
screen. Interestingly, only one of these drugs, BSI-201, has gone 
into advanced clinical testing in phase III trials but was recently 
demonstrated to lack activity as a PARP inhibitor in vitro.24,25
Interestingly, a number of these pathways were linked 
to signal transduction downstream of activated mutant KRAS, 
which is present in the particular cell line employed for this 
screening. We validated that inhibition of one of these path-
ways, MEK/ERK, with the best-in-class drug trametinib, 
caused prolonged cell cycle arrest and significant growth 
delay in combination with radiation in a xenograft model.
Many drugs that have promising systemic activity in 
the stage 4 disease setting are increasingly moving forward 
in phase II-III testing. Although many of these drugs may be 
FDA approved for indications in advanced disease, the treat-
ments remain noncurative, because most of the cancers develop 
resistance to the drug therapy. As a better understanding of 
the acquired resistance becomes known, more drugs are being 
developed that could bypass the resistance mechanism(s) or to 
potentially prevent the development of these cellular resistance 
strategies. These efforts by academia and industry are leading 
to even more specific and potent drugs that inhibit pathways 
specific to the cancer cells and minimize cross reactivity with 
normal tissues. The effectiveness of these treatment strategies 
may be enhanced if they are brought to more curative setting 
in stage III disease where both systemic and local therapies are 
critically important to render cures for patients. Coupled with 
improved staging methods to identify high-risk patients with 
minimal residual or metastatic disease, drugs that can enhance 
radiotherapy and either having single agent activity or synergis-
tic effects with chemotherapy are ideally suited to the curative 
setting. Methods that can elucidate these synergistic activities 
with radiation may accelerate the translation of these drugs to 
clinical testing. HCSA is a new strategy that has the potential 
to fulfill this unmet need. The power of this assay is the ability 
to predict the specific pathways that enhance radiation effects 
when multiple compounds in the same class independently dem-
onstrate radiation enhancement effects within the same screen. 
However, the technique in its current form does have some limi-
tations, namely the inability to test doses of radiation larger than 
approximately 6 Gy because the high number of cells that are 
needed to overcome the effects with radiation alone is too great 
to make any sensitive measurement of drug effect. However, it 
has sufficient dynamic range between 2 and 4 Gy to make it 
amendable for screening drugs using these doses. Given the sen-
sitivity of the assay, it was also difficult to ascertain the radiosen-
sitive nature of compounds if they exert significant single agent 
activity, such as the HSP90 inhibitors, which are known sensitiz-
ers.26,27 It is possible that at doses below 10 pM, which was the 
lower limit used in these experiments, we will be able uncover 
the radiation enhancement effects. Thus, drugs with these higher 
potencies may need to be assessed separately at lower doses. 
Lastly, although HCSA appeared capable of recapitulating simi-
lar SF2 values when compared with tCSA in a number of cell 
lines, there were some (e.g., DU145) that had different radia-
tion sensitivity profiles or which could not form adequate colo-
nies in the HCSA. The problem of low PE or loosely associated 
colonies that impacts tCSA becomes a bigger issue in the small 
well format. Future studies will optimize conditions that may 
promote better colony formation for these difficult-to-use cells.
As drugs become more specific, these compounds act 
as “probes” for specific genes or pathways, and very quickly 
one can identify genetic susceptibilities for each cell line. By 
integrating the drug sensitivity profile for each cell line using 
the HCSA along with genomic, transcriptomic, and proteomic 
information, we should in the future be able to identify the 
molecular contexts that explain the synthetic lethal effects of 
these drugs on cells treated with radiation. This information, 
once extensively validated, could help personalize targeted 
therapies in combination with radiation in the clinic.28
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